Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

The company has obtained sale authorization of KeraHeal as a cell-based therapy product in 2006 and was registered as part of the industrial insurance benefits in 2009. In October 2015, we obtained sale authorization and industrial insurance benefit registration for Keraheal-Allo which is a thermosensitive hydrogel-type allogeneic keratinocyte therapy product. in 2019, CartiLife was granted sale authorization as an autologous ...
The company has obtained sale authorization of KeraHeal as a cell-based therapy product in 2006 and was registered as part of the industrial insurance benefits in 2009. In October 2015, we obtained sale authorization and industrial insurance benefit registration for Keraheal-Allo which is a thermosensitive hydrogel-type allogeneic keratinocyte therapy product. in 2019, CartiLife was granted sale authorization as an autologous chondrocyte derived cartilaginous cell therapy for structural restoration of cartilage defect and symptom alleviation.

List your booth number for exhibitions, ask us